Vertex Pharmaceuticals: Regulators Allow Expanded Use Of Cystic Fibrosis Medicines
22 December 2020 - 7:29AM
Dow Jones News
By Micah Maidenberg
Vertex Pharmaceuticals Inc. said U.S. regulators will allow
three of its cystic fibrosis medicines to treat more patients.
Vertex on Monday said the expanded availability for the three
therapies will allow more than 600 people with certain rare cystic
fibrosis mutations to potentially access its drugs Trikafta,
Symdeko or Kalydeco.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
December 21, 2020 15:14 ET (20:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2024 to May 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From May 2023 to May 2024
